Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.

Detalles Bibliográficos
Autores principales: Taketa, Tomoyo, Nakamura, Takahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077276/
https://www.ncbi.nlm.nih.gov/pubmed/33936630
http://dx.doi.org/10.1002/ccr3.3927
Descripción
Sumario:Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.

Ejemplares similares